{"id":817515,"date":"2025-02-25T08:16:56","date_gmt":"2025-02-25T13:16:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-provides-program-updates-and-announces-participation-at-td-cowen-45th-annual-healthcare-conference\/"},"modified":"2025-02-25T08:16:56","modified_gmt":"2025-02-25T13:16:56","slug":"terns-pharmaceuticals-provides-program-updates-and-announces-participation-at-td-cowen-45th-annual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-provides-program-updates-and-announces-participation-at-td-cowen-45th-annual-healthcare-conference\/","title":{"rendered":"Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference"},"content":{"rendered":"
\n

\n TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25<\/em>\n <\/p>\n

\n New TERN-701 data from ongoing U.S. healthy volunteer PK study shows improved drug-drug interaction profile compared to asciminib<\/em>\n <\/p>\n

\n Introduces TERN-601 Phase 2 FALCON obesity study design; on track to initiate study in early 2Q25 with 12-week data expected 2H25<\/em>\n <\/p>\n

\n Cash and cash equivalents expected to provide runway into 2028<\/em>\n <\/p>\n

FOSTER CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (\u201cTerns\u201d or the \u201cCompany\u201d) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that management will participate in the TD Cowen 45th<\/sup> Annual Healthcare Conference taking place from March 3-5, 2025 in Boston and provided program updates across the Company\u2019s development programs as outlined below.<\/p>\n

\u201cSince our positive interim data readout from the TERN-701 CARDINAL study, we have maintained strong enrollment momentum and continue to see compelling safety and clinical activity across the dose range. We look forward to sharing additional data from CARDINAL later this year,\u201d said Emil Kuriakose, chief medical officer at Terns. \u201cAdditionally, we are excited to share new drug-drug interaction (DDI) data showing TERN-701 has a superior DDI profile compared to asciminib, allowing for safer co-administration of many commonly prescribed drugs, including statins. This is meaningful for patients with chronic myeloid leukemia (CML) who are on life-long therapy with tyrosine kinase inhibitors (TKIs). The compelling early data from CARDINAL, along with the lack of food effect and improved DDI compared to asciminib, reinforce TERN-701’s class-leading potential in CML.\u201d<\/p>\n

\u201cOral, small molecule GLP-1R agonists have shown meaningful, consistent weight loss in clinical trials over 12-weeks. However, the major limitation within the class continues to be poor gastrointestinal tolerability, necessitating complicated dose titration schedules that are burdensome for patients,\u201d said Amy Burroughs, chief executive officer at Terns. \u201cThe unique pharmaceutical properties of TERN-601 allowed for rapid titration in our 28-day Phase 1 study, resulting in competitive weight loss without dose interruptions, reductions, or discontinuations. Our goal in Phase 2 is to generate 12-week data that achieves competitive weight loss and best-in-class tolerability without the need for complicated dose titrations. Further establishing this differentiated profile will be an important catalyst in determining next steps for the program.\u201d<\/p>\n

\n Program Updates<\/strong>\n <\/p>\n

\n TERN-701: Oral, allosteric BCR-ABL tyrosine kinase inhibitor (TKI) for chronic myeloid leukemia (CML)<\/u>\n <\/p>\n